Hospital admissions, outpatient visits and healthcare costs of community‐dwellers with Alzheimer's disease

Tolppanen, Anna‐Maija; Taipale, Heidi; Purmonen, Timo; Koponen, Marjaana; Hartikainen, Sirpa

doi:10.1016/j.jalz.2014.10.005

Cited by 31 publications

(32 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, 1 study reported a 72% lower odds for PWD to have a LOS of 10 days or more compared to PwoD (95% CI: 0.1‐0.4) . With exception of 1 study conducted in Ireland, the remaining studies across Europe reported a longer LOS for PWD of up to 22 days . Within countries, the different studies were consistent in reporting a longer LOS for PWD compared to PwoD; however, the difference in the LOS varied up to 13 days …”

Section: Resultsmentioning

confidence: 93%

“…Eleven studies had a small sample size (range: 42‐395), were conducted in a single hospital (‐ward), or showed a sex distribution not representative of the PWD population . Thirty‐three studies met the criteria for comparability based on design or analysis, thereof 8 studies controlled or matched for 1 factor and 25 studies for at least 2 factors . Fourteen studies reported multivariate and descriptive results for LOS, and 5 studies solely multivariate results .…”

Section: Resultsmentioning

confidence: 99%

“…Thirty‐three studies met the criteria for comparability based on design or analysis, thereof 8 studies controlled or matched for 1 factor and 25 studies for at least 2 factors . Fourteen studies reported multivariate and descriptive results for LOS, and 5 studies solely multivariate results . Thirteen studies did not report any information on significance level …”

Section: Resultsmentioning

confidence: 99%

“…Seventeen studies across 7 countries were conducted in Europe: 3 studies each in Italy, Germany, Ireland, and the UK, 2 studies from Austria and Finland, as well as 1 study from Spain . The difference in LOS among PWD compared to PwoD ranged from 0.4 to 22 days . None of the studies from Italy reported a significantly longer LOS for PWD.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Length of hospital stay and dementia: A systematic review of observational studies

Möllers

Stocker

Wei

et al. 2018

Int J Geriat Psychiatry

View full text Add to dashboard Cite

Objective Hospitalizations of people with dementia (PWD) are often accompanied by complications or functional loss and can lead to adverse outcomes. Unsystematic findings suggest an influence of comorbidities on the extent of differences in the length of hospital stay (LOS). This systematic review aimed to identify and evaluate all studies reporting LOS in PWD as compared to PwoD in general hospitals. Methods A systematic review of observational studies using PubMed and ISI Web of Knowledge. Inclusion criteria comprised original studies written in English or German, assessment of diagnosis of dementia, measurement of LOS, and comparison of people with and without dementia. Results Fifty‐two of 60 studies reported a longer hospitalization time for PWD compared to PwoD. The extent of the difference in LOS varied between and within countries as well as by type of primary morbidity (eg, injuries, cardiovascular diseases). The range of the LOS difference for studies without restriction to a primary morbidity was −2 to +22 days after matching or adjustment for a variable number and selection of potentially relevant covariates. For studies with injuries/fractures/medical procedures and infectious/vascular disease as the primary morbidity, the range was −2.9 to +12.4 and −11.2 to +21.8 days, respectively. Conclusions The majority of studies reported a longer hospitalization of PWD compared to PwoD. Length of hospital stay seems to be influenced by a variety of medical, social, organizational factors, including reasons for hospital admission, whose role should be explored in detail in further research.

show abstract

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Length of hospital stay and dementia: A systematic review of observational studies

Möllers

Stocker

Wei

et al. 2018

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…In 2014, a French study showed that the average total monthly costs of AD were €2450 using the proxy good method, and €3102 using the opportunity cost method [11]. In the same year, a study in Finland indicated that the medical costs of an AD patient were €23,059 per person per year [12]. Thus, AD creates a heavy burden to both patients’ families and society and is also a huge challenge to economic development and elderly healthcare.…”

Section: Introductionmentioning

confidence: 99%

Monetary costs of Alzheimer’s disease in China: protocol for a cluster-randomised observational study

Chen

Wei

et al. 2017

BMC Neurol

View full text Add to dashboard Cite

BackgroundAlzheimer’s disease (AD) is the most common type of dementia. International multilateral cost-of-illness (COI) studies have revealed that the cost of treating this disease is huge, which places a significant burden on patients’ families and their healthcare systems. However, no such studies have been conducted in China. This study estimates the monetary costs of patients with AD in mainland China.MethodsThis study planned to start in October 2015 and to finish in March 2016. It covered 30 provincial, municipal, and autonomous regions in mainland China. The sites and research centres in each region were selected randomly. The participating sites include Tier 3 hospitals, psychiatric hospitals, geriatric hospitals, nursing homes, and residences. More than 2500 patients with AD and their caregivers from all of the 81 research centres will be enrolled to fulfil the calculated sample size. The monetary costs of AD, which include direct medical costs, direct non-medical costs, and indirect costs, are being collected using the electronic medical record system and residence health system at each site; face-to-face interviews are being performed when necessary. Descriptive statistics will be used to summarise the patient characteristics and generalised linear models will be developed to calculate the costs.ResultsThe main findings will include national and per patient annual monetary costs of AD in China.ConclusionsTo the best of our knowledge, this is the first large-scale cluster-randomized observational study to estimate the economic burden of AD in Chinese patients. The methodology used was based on China’s current healthcare system and is suitable for the purpose of the study. Because the burden of AD on patients, families, healthcare providers, and society is substantial and increasing, it is important and necessary to understand the economic burden caused by this disease.Trial registrationOur trial was retrospectively registered on ClinicalTrials.gov, NCT02694445, registered on 02/26/2016

show abstract

Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study

Saarelainen

Tolppanen

Koponen

et al. 2017

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Hospital admissions, outpatient visits and healthcare costs of community‐dwellers with Alzheimer's disease

Abstract: It would be important to assess whether inpatient hospitalizations of AD patients could be decreased by better targeting of outpatient services and whether other conditions are underdiagnosed or undertreated among persons with AD.

Cited by 31 publications

References 18 publications

Length of hospital stay and dementia: A systematic review of observational studies

Length of hospital stay and dementia: A systematic review of observational studies

Monetary costs of Alzheimer’s disease in China: protocol for a cluster-randomised observational study

Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study

Contact Info

Product

Resources

About